Importantly, IDH1 mutation confers a distinctive survival advantage in glioma patients; large cohort studies confirmed a 2-fold increase of median overall survival in glioblastoma patients and a more than threefold increase in lower-grade glioma patients compared with their respective controls46,47. This evidence concerns the gene IDH1 and central nervous system cancer.